Jalyn Approval History
Jalyn is a combination of dutasteride (5α-reductase inhibitor) and tamsulosin (alpha-adrenergic antagonist) indicated for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate.
Development History and FDA Approval Process for Jalyn
|Jun 14, 2010||FDA approves Jalyn, a fixed-dose combination of dutasteride and tamsulosin, for symptomatic BPH in men with an enlarged prostate|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.